Psychosis Clinical Trials

54 recruiting

Frequently Asked Questions

Common questions about Psychosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 96 trials

Recruiting
Phase 2Phase 3

ACP-204 in Adults With Alzheimer's Disease Psychosis

Alzheimer's Disease Psychosis
ACADIA Pharmaceuticals Inc.1,074 enrolled143 locationsNCT06159673
Recruiting
Not Applicable

Study of Self-Recognition and Self/Other Distinction Disorders in Patients With Psychological Vulnerability

Psychotic DisorderPsychosis of Childhood Borderline
University Hospital, Brest34 enrolled1 locationNCT04945278
Recruiting
Not Applicable

Cerebellar Modulation of Cognition in Psychosis

SchizophreniaPsychosisSchizoaffective Disorder+1 more
Mclean Hospital95 enrolled2 locationsNCT06107764
Recruiting

Cerebellum-based Imaging Neural Markers for Antipsychotic Response

Psychosis; Acute
Northwell Health120 enrolled1 locationNCT07483294
Recruiting
Not Applicable

Acute Psychiatric Care at Home for Lower-risk Patients With Acute Psychiatric Illness Who Require Inpatient Care

DepressionAnxietyPsychosis+1 more
Brigham and Women's Hospital45 enrolled3 locationsNCT07364825
Recruiting

Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services

SchizophreniaSchizoaffective DisorderDelusional Disorder+4 more
Beth Israel Deaconess Medical Center320 enrolled6 locationsNCT06740383
Recruiting
Phase 2

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

Psychosis Associated With Alzheimer's Disease
MapLight Therapeutics300 enrolled26 locationsNCT06887192
Recruiting
Phase 3

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics800 enrolled412 locationsNCT05980949
Recruiting

Psychiatric Symptom Predictors in Methamphetamine-Induced Psychosis

Methamphetamine Induced Psychosis
Elazığ Mental Health and Diseases Hospital150 enrolled1 locationNCT07459257
Recruiting

A Novel Blood Test as a Biomarker in Mental Health

Depression - Major Depressive DisorderSubstance Use DisordersAlcohol Use Disorder+5 more
Fraser Health500 enrolled1 locationNCT06856161
Recruiting
Not Applicable

Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Disorders

SchizophreniaSchizophrenia Spectrum DisordersPsychotic Disorders+3 more
Charite University, Berlin, Germany60 enrolled1 locationNCT07395206
Recruiting

LRFN5 and OLFM4 in Methamphetamine-Induced Psychosis

Methamphetamine Induced PsychosisMethamphetamine Use Disorder
Elazığ Mental Health and Diseases Hospital120 enrolled1 locationNCT07450027
Recruiting
Phase 3

A Study Evaluating the Efficacy of Xanomeline/Trospium (XT) on Cognitive Impairment After 24 and 52 Weeks of Treatment in Adult Participants With Schizophrenia

Cognitive ImpairmentSchizophrenia; Psychosis
European Group for Research In Schizophrenia171 enrolled16 locationsNCT07084831
Recruiting
Not Applicable

Enhanced Coordinated Specialty Care for Early Psychosis

SchizophreniaBipolar DisorderPsychosis+2 more
Mclean Hospital350 enrolled5 locationsNCT06071858
Recruiting
Not Applicable

Normobaric Oxygen Therapy for Individuals With First-Episode Psychosis

SchizophreniaPsychosisFirst-episode Psychosis
Nicholas Breitborde20 enrolled1 locationNCT04368039
Recruiting
Not Applicable

Precision Brain Stimulation to Reduce Cannabis Craving in Schizophrenia

SchizophreniaCannabis UsePsychosis+1 more
Vanderbilt University Medical Center100 enrolled1 locationNCT07196462
Recruiting
Phase 3

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

Psychosis Associated With Alzheimer's Disease
Karuna Therapeutics380 enrolled116 locationsNCT05511363
Recruiting

Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum

PregnancySchizophreniaPsychosis+5 more
University of Liverpool125 enrolled6 locationsNCT05766007
Recruiting
Phase 2

Effects of Tirzepatide on Alcohol Intake in Patients Diagnosed With Schizophrenia and Alcohol Use Disorder

SchizophreniaAlcoholismSchizophrenia Disorders+5 more
Anders Fink-Jensen, MD, DMSci108 enrolled2 locationsNCT06939088
Recruiting
Not Applicable

Neural Basis of Social Cognition Deficits

Autism Spectrum DisorderPsychosisSocial Communication
Loma Linda University90 enrolled1 locationNCT05185128